The costs used for the analysis of cost-effectiveness with plausible ranges and distributions for a sensitivity analysis
| Item . | Value . | Range . |
|---|---|---|
| US analysis | ||
| Treatment costs in USD | ||
| Office visit | 109 | |
| Drug payments, per daily dose | ||
| Imatinib, branded, 400 mg | 337 | |
| Imatinib, generic, 400 mg | 12 to 201 | |
| Dasatinib, 100 mg | 456 | |
| Nilotinib, 600 mg | 491 | |
| Nilotinib, 800 mg | 491 | |
| Annual costs used in the model health states in USD | ||
| Chronic phase, first year | ||
| Imatinib | 124 141 | 5 469 to 142 762 |
| Dasatinib | 167 508 | 124 141 to 192 634 |
| Nilotinib | 180 268 | 124 141 to 207 308 |
| Chronic phase, subsequent years | ||
| Imatinib | 123 594 | 4 922 to 142 133 |
| Dasatinib | 166 960 | 123 594 to 192 004 |
| Nilotinib | 179 721 | 123 594 to 206 679 |
| Allogeneic transplantation | 544 178 | 489 944 to 604 353 |
| Treatment-free remission | ||
| First year | 1 313 | 1 116 to 1 510 |
| Subsequent years | 438 | 372 to 503 |
| After allogeneic transplantation | ||
| First year | 2 298 | 1 953 to 2 643 |
| Subsequent years | 1 313 | 1 116 to 1 510 |
| Japanese analysis | ||
| Treatment costs in Japan in JPY (USD)* | ||
| Detailed examination at diagnosis | 120 230 (1 098) | |
| Routine clinical visit | 2 970 (27) | |
| BCR-ABL IS | 25 200 (230) | |
| Drug payments, per daily dose | ||
| Imatinib, branded, 400 mg | 9 214 (84) | |
| Imatinib, generic, 400 mg | 2 125 to 8 016 (19-73) | |
| Dasatinib, 100 mg | 18 955 (173) | |
| Nilotinib, 600 mg | 14 468 (132) | |
| Nilotinib, 800 mg | 18 955 (173) | |
| Annual costs used in the model health states in JPY (USD) | ||
| Chronic phase, first year | ||
| Imatinib | 3 614 950 (33 013) | 1 027 392 to 4 157 192 |
| Dasatinib | 7 170 415 (65 483) | 3 614 950 to 8 245 977 |
| Nilotinib | 5 532 660 (50 527) | 3 614 950 to 8 245 977 |
| Chronic phase, subsequent years | ||
| Imatinib | 3 475 790 (31 742) | 888 232 to 3 997 159 |
| Dasatinib | 7 031 255 (64 212) | 3 475 790 to 8 085 943 |
| Nilotinib | 5 393 500 (49 255) | 3 475 790 to 8 085 943 |
| Nilotinib, second line | 7 031 255 (64 212) | 3 475 790 to 8 085 943 |
| Treatment-free remission | ||
| First year | 338 040 (3 087) | 287 334 to 388 746 |
| Subsequent years | 112 680 (1 029) | 95 778 to 129 582 |
| Allogeneic transplantation | 8 337 907 (76 145) | 7 087 221 to 9 588 594 |
| After allogeneic transplantation | ||
| First year | 136 440 (1 246) | 115 974 to 156 906 |
| Subsequent years | 112 680 (1 029) | 95 778 to 129 582 |
| Item . | Value . | Range . |
|---|---|---|
| US analysis | ||
| Treatment costs in USD | ||
| Office visit | 109 | |
| Drug payments, per daily dose | ||
| Imatinib, branded, 400 mg | 337 | |
| Imatinib, generic, 400 mg | 12 to 201 | |
| Dasatinib, 100 mg | 456 | |
| Nilotinib, 600 mg | 491 | |
| Nilotinib, 800 mg | 491 | |
| Annual costs used in the model health states in USD | ||
| Chronic phase, first year | ||
| Imatinib | 124 141 | 5 469 to 142 762 |
| Dasatinib | 167 508 | 124 141 to 192 634 |
| Nilotinib | 180 268 | 124 141 to 207 308 |
| Chronic phase, subsequent years | ||
| Imatinib | 123 594 | 4 922 to 142 133 |
| Dasatinib | 166 960 | 123 594 to 192 004 |
| Nilotinib | 179 721 | 123 594 to 206 679 |
| Allogeneic transplantation | 544 178 | 489 944 to 604 353 |
| Treatment-free remission | ||
| First year | 1 313 | 1 116 to 1 510 |
| Subsequent years | 438 | 372 to 503 |
| After allogeneic transplantation | ||
| First year | 2 298 | 1 953 to 2 643 |
| Subsequent years | 1 313 | 1 116 to 1 510 |
| Japanese analysis | ||
| Treatment costs in Japan in JPY (USD)* | ||
| Detailed examination at diagnosis | 120 230 (1 098) | |
| Routine clinical visit | 2 970 (27) | |
| BCR-ABL IS | 25 200 (230) | |
| Drug payments, per daily dose | ||
| Imatinib, branded, 400 mg | 9 214 (84) | |
| Imatinib, generic, 400 mg | 2 125 to 8 016 (19-73) | |
| Dasatinib, 100 mg | 18 955 (173) | |
| Nilotinib, 600 mg | 14 468 (132) | |
| Nilotinib, 800 mg | 18 955 (173) | |
| Annual costs used in the model health states in JPY (USD) | ||
| Chronic phase, first year | ||
| Imatinib | 3 614 950 (33 013) | 1 027 392 to 4 157 192 |
| Dasatinib | 7 170 415 (65 483) | 3 614 950 to 8 245 977 |
| Nilotinib | 5 532 660 (50 527) | 3 614 950 to 8 245 977 |
| Chronic phase, subsequent years | ||
| Imatinib | 3 475 790 (31 742) | 888 232 to 3 997 159 |
| Dasatinib | 7 031 255 (64 212) | 3 475 790 to 8 085 943 |
| Nilotinib | 5 393 500 (49 255) | 3 475 790 to 8 085 943 |
| Nilotinib, second line | 7 031 255 (64 212) | 3 475 790 to 8 085 943 |
| Treatment-free remission | ||
| First year | 338 040 (3 087) | 287 334 to 388 746 |
| Subsequent years | 112 680 (1 029) | 95 778 to 129 582 |
| Allogeneic transplantation | 8 337 907 (76 145) | 7 087 221 to 9 588 594 |
| After allogeneic transplantation | ||
| First year | 136 440 (1 246) | 115 974 to 156 906 |
| Subsequent years | 112 680 (1 029) | 95 778 to 129 582 |
γ distributions were used in the probabilistic sensitivity analysis. Exchange rate, 1 USD = 109.5 JPY.
JPY, Japanese yen; USD, US dollar.
Japanese national health insurance price listed in 2018.